Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic biology company that went public through a merger with Soaring Eagle Acquisition Corp., sponsored by Eagle Equity Partners, in September 2021. The Boston-based company operates in the biotechnology sector, offering a cell programming platform that supports biosecurity and biological production services across pharmaceuticals, agriculture, and industrial applications. Ginkgo filed a Form 10-Q with the SEC on May 7, 2026, reporting results for the quarter ended March 31, 2026. Since its de-SPAC debut, the company has undergone significant restructuring, including workforce reductions and a strategic narrowing toward AI-enabled synthetic biology and biosecurity. Sign up at SpacDesk for full filing data, financial metrics, and analytics on DNA and hundreds of other post-merger SPAC companies.